HCPCS Level II code Q5129 designates a 10 mg unit of bevacizumab-adcd (Vegzelma), a biosimilar formulation of the anti-VEGF monoclonal antibody bevacizumab used primarily in oncology and some ophthalmic treatments. The code is important for accurately capturing biosimilar drug utilization and costs across outpatient infusion settings and physician offices, supporting billing consistency as biosimilars expand in clinical use.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national-level overview of how the code is used, what settings it typically applies to, and the clinical context for bevacizumab biosimilar administration. The publication outlines benchmarking elements relevant to payers and providers, summarizes recent policy considerations affecting biosimilar coding and coverage, and clarifies operational points such as service type and typical site of service.

This summary equips billing managers, revenue cycle staff, and policy analysts with concise information on code definition, clinical application, and payer relevance. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.